Study Group: Orlistat Prescribers for Obesity: Endocrinologists (US)(?)
Council Members in this Study Group: 20
Request a survey with this Study Group
Leading Experts in this Study Group
Harold Bays, MD, FACP
President and Medical Director
L-MARC Research Center
Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...
Joseph Bass, MD, PhDDivision Head of Endocrinology and Metabolism
Evanston Northwestern Healthcare
Joseph Bass, MD, PhD, is Assistant Professor of Medicine and Neurobiology at Northwestern University in Illinois and Division Head of Endocrinology and Metabolism at Evanston Northwestern Healthcare. He is also the Director of a federally-funded basic research program on obesity, diabetes, and lipid...
Director of Metabolism Section
University of Utah
Eliot Brinton, MD, is Director of Metabolism Section and Cardiovascular Genetics and Associate Professor of Medicine at the University of Utah specializing in lipid management and preventive cardiology. He has clinical expertise in lipid management and atheroprevention, treatment and prevention of diabetes...
Farhad Zangeneh, MDAssistant Clinical Professor of Medicine
THE GEORGE WASHINGTON UNIVERSITY - CC
Farhad Zangeneh, MD, is an Assistant Clinical Professor of Medicine at George Washington University School of Medicine in District of Columbia. He is on the board of directors of ACCE and recently contributed to the AACE Diabetes guidelines. He is the Medical Director of Endocrine, Diabetes and Osteoporosis...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
A flawed analysis that is unlikely to have as large an impact as financial pressure to prescribe generic simvastatin
This is an interesting analysis that may be scientifically flawed (because it was based on observational data that is subject to selection, medication compliance and comorbidity biases). It may encourage some prescribers to use Lipitor rather than simvastatin. However, that propensity may continue to...
This analysis of a completed trial suggests that patients using statins plus ezetimibe to achieve an LDL of under 70, had better regression of atherosclerosis than patients with an LDL target of under 100. In addition, the ezetimibe plus statin group did just as well as a group that used statins alone...
At first, it appeared that the reports linking Byetta and pancreatitis were likely due to an association between pancreatitis and the underlying pathology in patients receiving Byetta (obesity, diabetes, gall stones, and hypertriglyceridemia). However, the additional cases of (sometimes fatal)...
The co-marketing with Abbott will undoubtedly help Crestor sales, if they can effectively develop a fenofibrate-rosuvastatin combination, and avoid over-burdening physicians with reps. However, there are other factors that will probably have a larger impact.
Given what happened to Galvus, and the similar poor selectivity of saxagliptin for DPP-4 over other isoforms, I think that FDA approval is unlikely. There was also some data on changes in white count presented at the ADA that will hurt this agent. The FDA move to recommend outcome studies for DM treatments...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Contract Research Organization, Independent/Small
- Hospice Facility
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Partner
- Physician - Division Head
- Owner
- President